Revelation Biosciences, Inc. REVB
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Revelation Biosciences, Inc. (REVB) is a healthcare company listed in the US with a market value of about $2M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -282%.
About Revelation Biosciences
Revelation Biosciences is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. It was profitable in 0 of the last 7 years in our data. Its share count rose by 164611% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Net income | -$9M | -$15M | -$120254 | -$11M | -$12M | -$2M | -$3638 |
| Free cash flow | — | -$18M | — | — | -$11M | — | — |
| EPS (diluted) | $-23.95 | $-1052.16 | $-101.28 | $-28734.00 | $-8184.95 | $-130.96 | — |
| Net margin | — | — | — | — | — | — | — |
| ROIC | -74.6% | -133.8% | -102.9% | -815.5% | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $124.25, 2813% above the current price; targets range from $112.00 to $136.50; the consensus rating is “none”; expected EPS is $-33.98 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Revelation Biosciences pay a dividend?
Not currently.
Is Revelation Biosciences a good stock to buy?
We do not give buy or sell advice. Revelation Biosciences scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.